Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
06 juin 2024 09h00 HE
|
Tiziana Life Sciences Ltd.
Qualitative improvements in PET imaging seen in 80% of non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access patients receiving intranasal foralumab for at least 6-months.FDA...
Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research
30 mai 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Bragar Eagel & Squire, P.C. Is Investigating Zoetis, and Morgan Stanley and Encourages Investors to Contact the Firm
07 mai 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Zoetis Inc. (NYSE: ZTS),...
MS INVESTOR NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Morgan Stanley Investors to Inquire About Securities Class Action Investigation – MS
04 mai 2024 11h06 HE
|
The Rosen Law Firm PA
NEW YORK, May 04, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Morgan Stanley...
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
26 avr. 2024 09h23 HE
|
Tevogen Bio Inc
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
25 avr. 2024 10h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Bragar Eagel & Squire, P.C. Is Investigating Zoetis, and Morgan Stanley and Encourages Investors to Contact the Firm
23 avr. 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Zoetis Inc. (NYSE: ZTS),...
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
23 avr. 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
22 avr. 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months of Follow-upAll Patients Have Either Stabilized or Improved on Nasal...
Bragar Eagel & Squire, P.C. Is Investigating CI&T, Harbor, AXTI, and Morgan Stanley and Encourages Investors to Contact the Firm
19 avr. 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CI&T Inc. (NYSE:...